Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO

CERo Therapeutics

CERO THERAPEUTICS HOLDINGS, INC.

CERo Therapeutics clinical programs — 26 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
Status
Public
HQ
201 Haskins Way, 230, South San Francisco, California 94080, US
Employees
17
Programs
47
Drugs
84
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

CERo Therapeutics projects

26 ClinicalTrials.gov programs sponsored by CERo Therapeutics.

CERo Therapeutics has 26 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

26 programs

Clinical programs

  1. Cyramza /ml concentrate for stomach cancer stage IV with me…

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  2. Dopacis 90 MBq/ml oplossing voor injectie

    CERO THERAPEUTICS HOLDINGS, INC.

    patients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRI

    phase 2 small molecule active

    1 trial

  3. ENGIC 01-COLOSOTO

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  4. FFCD 1605 OPTIPRIME

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. FFCD 1709 - SIRTCI

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  6. FFCD 2006 NEORAF

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  7. FFCD1703

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  8. FRUZAQLA hard capsules for métastatique colorectal cancer

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

  9. Fianlimab for Pleural mesothelioma

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  10. ICO-2020-01 REPAIR

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  11. ICO-2023-10

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  12. ICO-2023-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  13. ICO-N-2013-03

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  14. IFCT-1904

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. IFCT-2003

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  16. IFCT-2101

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  17. IFCT-2401 SPORADIC

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. IFCT-2502

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  21. PRODIGE 104 A

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. PRODIGE 111

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. PRODIGE 34 - ADAGE

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  24. Prodige 54 SAMCO

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  25. TEP-64Cu-ATSM-Rectum

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  26. ivonescimab

    CERO THERAPEUTICS HOLDINGS, INC.

    pleural mesothelioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does CERo Therapeutics have?

26 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.